BridgeMD
New treatment option for Myocardial Infarction, Acute
Official title Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)
ClinicalTrials.gov ID: NCT04968808
What this study is testing
- What it's testing
- Many patients with non-ST-segment elevation myocardial infarction (NSTEMI) have multivessel coronary artery disease (MVD), which is associated with poor clinical outcomes. However, there have been few studies regarding revascularization strategy in patients with NSTEMI and MVD.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 and older
You may be able to join if
- Age ≥ 19 years old
- Non-ST-segment elevation myocardial infarction
- Angina pectoris or equivalent ischemic chest discomfort with at least 1 of 3 features and,
- occurs at rest, usually lasting \> 10 minutes
- severe and new onset (within the prior 4-6 weeks)
You likely can't join if
- Cardiogenic shock at initial presentation or after treatment of IRA
- TIMI flow at non-IRA ≤ 2
- Severe procedural complications (e.g. persistent no-reflow phenomenon, coronary artery perforation) which restricts study enrollment by operators'...
- Non-IRA lesion not suitable for PCI treatment by operators' decision
- Chronic total occlusion at non-IRA
- History of anaphylaxis to contrast agent
See the full eligibility criteria
- Age ≥ 19 years old
- Non-ST-segment elevation myocardial infarction
- Angina pectoris or equivalent ischemic chest discomfort with at least 1 of 3 features and,
- occurs at rest, usually lasting \> 10 minutes
- severe and new onset (within the prior 4-6 weeks)
- crescendo pattern
- Elevated cardiac biomarkers and,
- ≥ 99% value of high-sensitivity cardiac troponin
- No ST-segment elevation ≥ 0.1 mV in ≥ 2 contiguous leads or newly developed left bundle branch block on 12-lead electrocardiogram
- PCI within 72 hours after symptom development
- Multivessel disease: Non-IRA with at least 2.5 mm diameter and 50% diameter stenosis by visual estimation
- Patient's or protector's agreement about study design and the risk of PCI
- Cardiogenic shock at initial presentation or after treatment of IRA
- TIMI flow at non-IRA ≤ 2
- Severe procedural complications (e.g. persistent no-reflow phenomenon, coronary artery perforation) which restricts study enrollment by operators' decision
- Non-IRA lesion not suitable for PCI treatment by operators' decision
- Chronic total occlusion at non-IRA
- History of anaphylaxis to contrast agent
- Pregnancy and lactation
- Life expectancy \< 1-year
- Severe valvular disease
- History of CABG, or planned CABG
- Fibrinolysis before admission
The study team makes the final eligibility decision.
Where it's taking place
- Gwangju, South Korea
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Gwangju, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.